Cytogenetics of Chronic Myeloid Leukemia (CML)
The Biology and Pathogenesis of Chronic Myeloid Leukaemia
Epidemiology of Chronic Myeloid Leukemia.-Imatinib and the first line CML Therapy
CML Therapy: A Focus on Second and Third Generation Tyrosine Kinase Inhibitors
Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
Pharmacoeconomic considerations for tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update
Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death
A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia
The Role of Hematopoietic Stem Cell Transplantation in CML
CML end-phase and blast crisis: implications and management
The Interferon-alpha Revival in CML
Managing Pregnancy in Chronic Myeloid Leukemia
Response-Related Predictors of Survival and of Treatment Free Remission in CML
Discontinuation or cessation of tyrosine kinase inhibitor treatment in Chronic myeloid leukemia patients with deep molecular response.